Search results
Showing 31 to 45 of 73 results for hepatocellular carcinoma
This guideline covers assessing and managing suspected or confirmed cirrhosis in people who are 16 years or older. It aims to improve how cirrhosis is identified and diagnosed, and gives advice on the monitoring, prevention and early management of complications.
Awaiting development Reference number: GID-TA11019 Expected publication date: TBC
Awaiting development Reference number: GID-TA10911 Expected publication date: TBC
Tenofovir disoproxil for the treatment of chronic hepatitis B (TA173)
Evidence-based recommendations on tenofovir disoproxil for treating chronic hepatitis B.
Irreversible electroporation for primary liver cancer (HTG532)
Evidence-based recommendations on irreversible electroporation for primary liver cancer in adults. This involves passing short electrical pulses of high-voltage current into the cancer cells.
View recommendations for HTG532Show all sections
Our centralised approach to prioritising our guidance topics ensures that we produce guidance that's relevant, timely, accessible, and has demonstrable impact.
Evidence-based recommendations on laparoscopic liver resection. This involves making small incisions (keyhole surgery) to remove the parts of the liver that are benign or cancerous.
View recommendations for HTG83Show all sections
Sections for HTG83
Elafibranor for previously treated primary biliary cholangitis (TA1016)
Evidence-based recommendations on elafibranor (Iqirvo) for previously treated primary biliary cholangitis in adults.
Nivolumab for untreated advanced hepatocellular carcinoma [ID1248]
Discontinued Reference number: GID-TA10221
Pembrolizumab for previously treated advanced hepatocellular carcinoma [ID1458]
Discontinued Reference number: GID-TA10380
Cabozantinib with atezolizumab for untreated advanced hepatocellular carcinoma [ID3940]
Discontinued Reference number: GID-TA10830
Awaiting development Reference number: GID-TA11222 Expected publication date: TBC
Awaiting development Reference number: GID-TA11653 Expected publication date: TBC
Discontinued Reference number: GID-TA10811
Evidence-based recommendations on melphalan chemosaturation with percutaneous hepatic artery perfusion and hepatic vein isolation for primary or metastatic cancer in the liver. This involves diverting the blood flow from the liver to the rest of the body while the drug is delivered directly into the liver.
View recommendations for HTG575Show all sections